How to Conduct Clinical Trials for Medical Devices in China

How to Conduct Clinical Trials for Medical Devices in China

Over 35% of global medical device innovations now require China-specific clinical data for market registration — a trend driven by the National Medical Products Administration (NMPA) increasingly demanding local clinical evidence rather than accepting foreign trial results by default. For foreign medical device manufacturers seeking to enter the world’s second-largest healthcare market, navigating China’s clinical trial requirements is one of the most critical—and complex—regulatory hurdles. This guide provides a comprehensive roadmap for planning, conducting, and managing clinical trials for medical devices in China under the current regulatory framework.

Understanding When Clinical Trials Are Required for Medical Device Registration

Not all medical devices require a full clinical trial for NMPA registration. The regulatory pathway depends on the device classification and whether it has a predicate device already on the Chinese market. Under the NMPA’s 2021 revised regulations, Class I devices (low risk) are generally exempt from clinical evaluation. Class II devices (medium risk) may qualify for the Clinical Trial Exemption Catalogue — if the device is listed, the manufacturer can submit a clinical evaluation report instead of conducting a de novo trial. Class III devices (high risk) and Class II devices not on the exemption list must undergo a clinical trial. Devices using novel materials, new mechanisms of action, or implantable technologies almost always require a full clinical trial.

Foreign manufacturers should also assess whether their device can leverage the Acceptance of Overseas Clinical Trial Data Policy, introduced by the NMPA in 2018. Under this policy, clinical data generated outside China may be accepted for NMPA registration if the trial was conducted in accordance with Good Clinical Practice (GCP) standards equivalent to China’s, and the data meets China’s specific ethnic and demographic requirements. However, in practice, the NMPA often requests supplemental Chinese clinical data even when foreign data is accepted — particularly for devices where patient physiology differs significantly between Chinese and Western populations.

Navigating the NMPA Clinical Trial Approval Process

The NMPA clinical trial approval process consists of several sequential stages, each with defined timelines and documentation requirements. First, the manufacturer must submit a Clinical Trial Application (CTA) to the NMPA Center for Medical Device Evaluation (CMDE). The CTA dossier must include the device technical documentation, quality control data, preclinical study results, and a detailed clinical trial protocol. The NMPA has 60 working days to review the CTA — if no questions or objections are raised within this period, the trial is deemed approved.

Manufacturers should budget for at least 8–12 months from CTA submission to trial initiation, assuming no major deficiencies in the application. The NMPA may issue deficiency letters requiring additional data or protocol amendments, which can extend the timeline by 3–6 months per iteration.

Selecting Qualified Clinical Trial Sites and Investigators

The choice of clinical trial site is one of the most consequential decisions in the trial planning process. The NMPA requires that all clinical trials for medical devices be conducted at NMPA-certified clinical trial institutions — hospitals that have undergone rigorous inspection and maintain GCP-compliant infrastructure and personnel. As of 2025, China has over 1,100 certified clinical trial institutions for medical devices, concentrated primarily in first-tier cities such as Beijing, Shanghai, Guangzhou, and Chengdu.

Foreign manufacturers should consider several factors when selecting trial sites. Geographic diversity is important for ensuring the trial data represents China’s demographic and ethnic diversity — particularly for devices where anatomical or physiological differences may affect outcomes. The principal investigator (PI) must be a licensed physician with documented experience in clinical trials for the relevant therapeutic area. The NMPA requires that the PI has completed at least one GCP-trained clinical trial in the past three years. Language capabilities are a practical consideration — most clinical trial documentation in China is conducted in Mandarin Chinese, and the PI must be fluent in reading and writing medical Chinese for regulatory communications and adverse event reporting.

Understanding China’s Good Clinical Practice (GCP) Requirements

China’s clinical trial regulations are governed by the Medical Device Good Clinical Practice (GCP) Guidelines, which were significantly revised in 2022 to align more closely with international standards such as ISO 14155 and the ICH GCP guidelines. The 2022 revisions introduced several important changes that directly affect foreign sponsors conducting trials in China.

Key GCP requirements include mandatory electronic data capture (EDC) systems for all clinical trial data; expanded informed consent requirements including specific disclosures about genetic data collection; enhanced adverse event monitoring with expedited reporting timelines — serious adverse events must be reported to the NMPA within 7 calendar days; and risk-based monitoring plans rather than mandatory 100% source data verification. Foreign sponsors must appoint a local legal representative who bears regulatory responsibility for the trial in China. The GCP also mandates that all trial data remain in China unless an explicit data transfer agreement has been approved.

1. Appoint a qualified local legal representative for regulatory and liability purposes
2. Implement an NMPA-compliant EDC system with real-time data monitoring capabilities
3. Draft informed consent forms that explicitly address genetic data collection and biospecimen handling
4. Establish an adverse event reporting SOP that meets China’s 7-day serious adverse event timeline
5. Submit a risk-based monitoring plan to the ethics committee before trial initiation

Managing the Ethics Committee Review and Informed Consent Process

Every clinical trial for medical devices in China must receive approval from an Institutional Ethics Committee (IEC) — the Chinese equivalent of an Institutional Review Board (IRB). The IEC operates independently and is responsible for protecting the rights, safety, and well-being of trial participants. The NMPA requires that the IEC include at least seven members with diverse expertise, including medical, legal, and layperson perspectives.

The informed consent process in China has several distinctive features. Chinese regulations require that informed consent documents be written in Chinese and use plain language appropriate for the local population’s educational level. The consent form must explicitly disclose the device’s regulatory status — whether it is investigational, what alternative treatments exist, and the anticipated costs of participation. Genetic data collection requires separate, specific consent distinct from the general informed consent. For medical device trials, the consent form must also disclose whether the device will remain inside the patient’s body after the trial concludes, and for how long.

Foreign sponsors should be aware that literacy rates and health literacy vary significantly across China’s regions. In rural trial sites, the IEC may require verbal consent procedures augmented by witnessed consent, as some participants may have limited reading fluency. Ethics committee approval timelines vary by institution — major teaching hospitals in tier-1 cities typically complete reviews within 15–20 working days, while smaller institutions may require 30–45 days.

Budgeting for Clinical Trials in China: Cost Drivers and Typical Ranges

The total cost of conducting a medical device clinical trial in China varies widely depending on the device class, trial complexity, number of sites, and patient enrollment targets. As a general benchmark, a moderate-complexity Class III device trial with 200 patients across 5 sites can range from RMB 8–15 million (approximately USD 1.1–2.1 million). This typically represents a 30–50% cost savings compared to conducting the same trial in the United States or Western Europe, though the gap has narrowed in recent years as Chinese CRO costs have risen.

Major cost drivers include the NMPA registration and review fees — the CTA review fee for medical devices is approximately RMB 200,000–350,000 depending on device class. Ethics committee review fees range from RMB 20,000–80,000 per site. Investigator fees and site overhead costs account for approximately 40–50% of the total budget, with per-patient costs ranging from RMB 30,000–80,000 depending on the device category and follow-up duration. Clinical research organization (CRO) fees for full-service trial management add 15–25% overhead. Data management and biostatistics services add another 5–10%.

Cost-saving strategies include selecting trial sites outside tier-1 cities where overheads are lower, optimizing the protocol to reduce unnecessary follow-up visits, and leveraging existing NMPA-approved clinical trial institutions with established infrastructure. Foreign sponsors should also factor in the cost of regulatory consulting services for CTA preparation, which can add RMB 500,000–1,000,000 for complex Class III devices.

Common Pitfalls and How to Avoid Them

Foreign manufacturers conducting clinical trials in China frequently encounter several recurring challenges. One of the most common pitfalls is underestimating the regulatory timeline. Despite the 60-working-day CTA review period, the actual time from preparation to trial initiation often exceeds 12 months due to repeated deficiency letters from the CMDE. Mitigation: Engage a qualified local regulatory consultant to review the CTA dossier before submission and conduct a mock deficiency assessment.

Data sovereignty and cross-border data transfer restrictions have become a major compliance concern. China’s Personal Information Protection Law (PIPL) and the Data Security Law (DSL) impose strict requirements on the transfer of personal data — including clinical trial data — outside China. All clinical trial data generated in China must be stored on servers located within China. Export of trial data requires a security assessment conducted by the Cyberspace Administration of China (CAC), which can take 3–6 months to complete. Mitigation: Plan for China-based data storage from the outset and initiate the CAC assessment early in the trial planning phase.

• Language barrier in regulatory communications: All CTA submissions, deficiency responses, and final reports must be in Chinese. Engage bilingual regulatory specialists.
• GCP convergence issues: Despite the 2022 alignment with international GCP, specific Chinese requirements (e.g., mandatory CTA approval before ethics submission) still differ from ICH GCP.
• Site selection bias: Many foreign sponsors choose sites based on convenience rather than patient population representativeness, leading to NMPA questions about demographic adequacy.
• Genetic resource compliance: Collection and use of human genetic resources require separate approval under China’s Human Genetic Resources管理条例.

Where to Go From Here

Conducting a clinical trial for medical devices in China requires careful planning, significant investment, and deep regulatory expertise — but the commercial opportunity of the Chinese market makes it a strategic necessity for most global device manufacturers.

• Ready to act? Read a step-by-step guide to completing your NMPA clinical trial application
• Still comparing? See a side-by-side comparison of trial pathways in China vs. the EU and US
• Need numbers? Try an interactive cost calculator for medical device clinical trials in China

How to Conduct Clinical Trials for Medical Devices in China: Guide — first published on China Gateway 360. Last updated: July 2026.